Tidal’s technology platform to expand Sanofi’s research capabilities in immuno-oncology and inflammatory diseases.
Global biopharmaceutical company Sanofi has announced the acquisition of the Myeloma Investment Fund (MIF) portfolio company Tidal Therapeutics, a Cambridge, MA-based biotech developing a new technology platform for the treatment of cancer and inflammatory diseases.
Tidal’s platform uses mRNA to modify T cells directly in the patient’s body, reprogramming them to target myeloma and B cell malignancies. However, unlike existing CAR-T therapies, Tidal’s approach does not require the removal and reinfusion of the patient’s cells. With its acquisition, Sanofi will further develop the technology platform to expand its research capabilities in immuno-oncology and inflammatory diseases.
“We are thrilled to see Sanofi moving this novel technology forward in immuno-oncology,” said Peter Kosa, Ph.D., MBA, Managing Director of the Myeloma Investment Fund. “Its acquisition of Tidal demonstrates the viability of investing in cutting-edge companies that are driving promising precision medicine approaches to better treat and ultimately cure myeloma. With each investment, the MIF is advancing the next generation of therapies, and also helping to catalyze the biotech and venture capital community to fund the most innovative research in myeloma.”
The MIF was established in 2019 by the MMRF to accelerate the development of new myeloma therapies through venture investment. Since its launch, the MIF has invested in six portfolio companies developing innovative therapeutic approaches and technology platforms that may be used to treat multiple myeloma. To learn more about the MIF’s portfolio visit: https://myelomainvestmentfund.org/portfolio.
About the Myeloma Investment Fund
The Myeloma Investment Fund (MIF), is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to accelerate the delivery of precision medicine approaches and a cure to every multiple myeloma patient. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research, providing access to longstanding relationships with pharmaceutical companies and academic medical centers, a clinical network of 23 sites, and data from the largest genomics data set of any cancer. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit MyelomaInvestmentFund.org.